Treatment challenges persist in advanced lung cancer despite the development of therapies beyond the traditional platinum-based chemotherapy. The early 2000s marked a shift to tyrosine kinase inhibitors targeting epidermal growth factor receptor, ushering in personalized genetic-based treatment. A further significant advance was the development of immune checkpoint inhibitors (ICIs), especially for non–small cell lung cancer. These target programmed death-ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4, which enhanced the immune response against tumor cells. However, not all patients respond, and immune-related toxicities arise. This review emphasizes identifying biomarkers for ICI response prediction. While PD-L1 is a widely used, validated biomarker, its predictive accuracy is imperfect. Investigating tumor-infiltrating lymphocytes, tertiary lymphoid structure, and emerging biomarkers such as high endothelial venule, Human leukocyte antigen class I, T-cell immunoreceptors with Ig and ITIM domains, and lymphocyte activation gene-3 counts is promising. Understanding and exploring additional predictive biomarkers for ICI response are crucial for enhancing patient stratification and overall care in lung cancer treatment.
Every patient with advanced non–small cell lung cancer (NSCLC) should be tested for targetable driver mutations and gene arrangements that may open avenues for targeted therapy. As most patients with NSCLC in the advanced stage of the disease are not candidates for surgery, these tests have to be performed on small biopsies or cytology samples. A growing number of other genetic changes with targetable mutations may be treatable in the near future. To identify patients who might benefit from novel targeted therapy, relevant markers should be tested in an appropriate context. In addition, immunotherapy of lung cancer is guided by the status of programmed death-ligand 1 expression in tumor cells. The variety and versatility of cytological specimen preparations offer significant advantages for molecular testing; however, they frequently remain underused. Therefore, evaluating the utility and adequacy of cytologic specimens is important, not only from a lung cancer diagnosis, but also for the large number of ancillary studies that are necessary to provide appropriate clinical management. A large proportion of lung cancers is diagnosed by aspiration or exfoliative cytology specimens; thus, optimizing strategies to triage and best use the tissue for diagnosis and biomarker studies forms a critical component of lung cancer management. In this review, we discuss the opportunities and challenges of using cytologic specimens for biomarker testing of lung cancer and the role of cytopathology in the molecular era.
Citations
Citations to this article as recorded by
Molecular testing of cytology specimens: Issues in specimen adequacy and clinical utility Ghulam Ghous, Komal Ijaz, Magda Esebua, Lester J. Layfield Diagnostic Cytopathology.2024; 52(2): 123. CrossRef
The updated College of American Pathologists principles of analytic validation of immunohistochemical assays: A step forward for cytopathology Sinchita Roy‐Chowdhuri Cancer Cytopathology.2024;[Epub] CrossRef
High-throughput genomics and transcriptomics are often applied in routine pathology practice to facilitate cancer diagnosis, assess prognosis, and predict response to therapy. However, the proteins rather than nucleic acids are the functional molecules defining the cellular phenotype in health and disease, whereas genomic profiling cannot evaluate processes such as the RNA splicing or posttranslational modifications and gene expression does not necessarily correlate with protein expression. Proteomic applications have recently advanced, overcoming the issue of low depth, inconsistency, and suboptimal accuracy, also enabling the use of minimal patient-derived specimens. This review aims to present the recent evidence regarding the use of high-throughput proteomics in both exfoliative and fine-needle aspiration cytology. Most studies used mass spectrometry, as this is associated with high depth, sensitivity, and specificity, and aimed to complement the traditional cytomorphologic diagnosis, in addition to identify novel cancer biomarkers. Examples of diagnostic dilemmas subjected to proteomic analysis included the evaluation of indeterminate thyroid nodules or prediction of lymph node metastasis from thyroid cancer, also the differentiation between benign and malignant serous effusions, pancreatic cancer from autoimmune pancreatitis, non-neoplastic from malignant biliary strictures, and benign from malignant salivary gland tumors. A few cancer biomarkers—related to diverse cancers involving the breast, thyroid, bladder, lung, serous cavities, salivary glands, and bone marrow—were also discovered. Notably, residual liquid-based cytology samples were suitable for satisfactory and reproducible proteomic analysis. Proteomics could become another routine pathology platform in the near future, potentially by using validated multi-omics protocols.
Citations
Citations to this article as recorded by
Identification of NIFTP-Specific mRNA Markers for Reliable Molecular Diagnosis of Thyroid Tumors So-Yeon Lee, Jong-Lyul Park, Kwangsoon Kim, Ja Seong Bae, Jae-Yoon Kim, Seon-Young Kim, Chan Kwon Jung Endocrine Pathology.2023; 34(3): 311. CrossRef
Background MicroRNAs (miRNA/miR) play significant roles in the regulation of cell differentiation, cell cycle progression, and apoptosis. They become dysregulated during carcinogenesis and are eventually released into the circulation, enabling their detection in body fluids. Thus, this study compared the miRNA expression in tissue and plasma samples of colorectal cancer (CRC) patients and clinically healthy controls and determined miRNA expression as a potential CRC biomarker.
Methods Using quantitative reverse transcription polymerase chain reaction (RT-qPCR), miR-21-5p, miR-29a-3p, miR-92a-3p, miR-135b-5p, miR-196b-5p, and miR-197-3p, expression was analyzed and compared between the malignant (n = 41) and the adjacent neoplasm free mucosal tissues (n = 41) of CRC patients. The findings were validated in plasma samples (n = 36) collected from the same CRC patients prior to surgery or any form of treatment and compared to plasma from their age and sex-matched controls (n = 36).
Results MiR-21-5p, miR-29a-3p, miR-92a-3p, and miR- 196b-5p were upregulated and miR-135b-5p was downregulated in CRC malignant tissues compared to their expression in adjacent neoplasm-free tissue. This was further observed in the plasma of the same CRC cases compared to controls. MiR-92a-3p showed itself the most sensitive (0.93; p < .001) and most specific (0.95; p < .001) in detecting CRC in tissue. In plasma, miR-196b-5p was the most sensitive (0.97; p < .001) and specific (0.94; p < .001) in detecting CRC. Plasma miR-92a-3p and miR-196b-5p were the most sensitive (0.95; p < .001) and specific (0.94; p < .001) in the early detection of CRC.
Conclusions Results show that specific miRNAs dysregulated in malignant
tissues are released and can be detected in the circulation, supporting their potential as non-invasive biomarkers of CRC.
Citations
Citations to this article as recorded by
The Role of Extracellular Vesicles in Colorectal Cancer Yujian Xia, Chaoran Yu, Ernest Johann Helwig, Yousheng Li Technology in Cancer Research & Treatment.2023;[Epub] CrossRef
HNRNPA2B1-Mediated MicroRNA-92a Upregulation and Section Acts as a Promising Noninvasive Diagnostic Biomarker in Colorectal Cancer Yiling Li, Kexin Li, Xiaoying Lou, Yue Wu, Samuel Seery, Danfei Xu, Yuqing Pei, Benheng Qian, Yuxin Wu, Shuang Liang, Kui Wu, Wei Cui Cancers.2023; 15(4): 1367. CrossRef
Role of salivary miRNAs in the diagnosis of gastrointestinal disorders: a mini-review of available evidence Maria Oana Săsăran, Claudia Bănescu Frontiers in Genetics.2023;[Epub] CrossRef
Exploring the Role of Circulating Cell-Free RNA in the Development of Colorectal Cancer Chau-Ming Kan, Xiao Meng Pei, Martin Ho Yin Yeung, Nana Jin, Simon Siu Man Ng, Hin Fung Tsang, William Chi Shing Cho, Aldrin Kay-Yuen Yim, Allen Chi-Shing Yu, Sze Chuen Cesar Wong International Journal of Molecular Sciences.2023; 24(13): 11026. CrossRef
Lynch Syndrome Biopathology and Treatment: The Potential Role of microRNAs in Clinical Practice Serena Ascrizzi, Grazia Maria Arillotta, Katia Grillone, Giulio Caridà, Stefania Signorelli, Asad Ali, Caterina Romeo, Pierfrancesco Tassone, Pierosandro Tagliaferri Cancers.2023; 15(15): 3930. CrossRef
Background Polo-like kinase 4 (PLK4) is a serine/threonine protein kinase located in the centriole of the chromosome during the cell cycle. PLK4 overexpression has been described in a variety of many common human epithelial tumors. Conversely, PLK4 acts as a haploinsufficient tumor suppressor in some situations, highlighting the importance of strict regulation of PLK4 expression, activity, and function. Meanwhile, the importance of chemoradiation resistance in rectal cancer is being emphasized more than ever. We aimed to analyze PLK4 expression and the tumor regression grade (TRG) in patients with rectal cancer, treated with chemoradiotherapy (CRT).
Methods A retrospective study was conducted on 102 patients with rectal cancer who received preoperative CRT. Immunohistochemistry for PLK4 in paraffin-embedded tissue was performed from the biopsy and surgical specimens.
Results We found significant association between high expression of PLK4 and poor response to neoadjuvant CRT (according to both Mandard and The Korean Society of Pathologists TRG systems) in the pre-CRT specimens. Other clinicopathologic parameters did not reveal any correlation with PLK4 expression.
Conclusions This study revealed an association between high expression of PLK4 in the pre-CRT specimens and TRG. Our results indicated that PLK4 could potentially be a new predictor for CRT effect in patients with rectal cancer.
Background Acute kidney injury (AKI) is a common cause of morbidity and mortality. It mainly targets the renal tubular epithelium with pathological changes, referred to as acute tubular injury. The latter is followed by a regenerative response that is difficult to visualize on routine hematoxylin and eosin (H&E) stains. In this study, we examined the regenerative capacity of renal tubules by correlating vimentin (VIM) immunohistochemical (IHC) expression and pathological findings of AKI and renal tubular regeneration (RTR) on H&E.
Methods We reviewed 23 autopsies performed in the clinical setting of AKI and RTR. VIM expression was scored in the renal cortical tubular epithelium using a statistical cutoff ≥ 3% for high expression and < 3% for low expression.
Results Of the 23 kidney tissues examined, seven (30.4%) had low VIM expression, and 16 (69.6%) had high VIM expression. Kidney tissues with evidence of AKI and RTR had significantly higher VIM expression. Renal peritubular microenvironment features showing regenerative changes on H&E were associated with high VIM expression. In the univariate model, kidney tissues with RTR were 18-fold more likely to have high VIM expression.
Conclusions In conclusion, our findings suggest that VIM could serve as an IHC marker for RTR following AKI. However, correlation with H&E findings remains critical to excluding chronic tubular damage. Collectively, our preliminary results pave the way for future studies including a larger sample size to validate the use of VIM as a reliable biomarker for RTR.
Citations
Citations to this article as recorded by
Characterization of macrophages in ischemia–reperfusion injury-induced acute kidney injury based on single-cell RNA-Seq and bulk RNA-Seq analysis Qin Wang, Yuxing Liu, Yan Zhang, Siyuan Zhang, Meifang Zhao, Zhangzhe Peng, Hui Xu, Hao Huang International Immunopharmacology.2024; 130: 111754. CrossRef
Molecular biomarker testing is the standard of care for non–small cell lung cancer (NSCLC) patients. In 2017, the Korean Cardiopulmonary Pathology Study Group and the Korean Molecular Pathology Study Group co-published a molecular testing guideline which contained almost all known genetic changes that aid in treatment decisions or predict prognosis in patients with NSCLC. Since then there have been significant changes in targeted therapies as well as molecular testing including newly approved targeted drugs and liquid biopsy. In order to reflect these changes, the Korean Cardiopulmonary Pathology Study Group developed a consensus statement on molecular biomarker testing. This consensus statement was crafted to provide guidance on what genes should be tested, as well as methodology, samples, patient selection, reporting and quality control.
Citations
Citations to this article as recorded by
Clinical utility of the Oncomine Dx Target Test multi‐CDx system and the possibility of utilizing those original sequence data Ayaka Saito, Hideki Terai, Tae‐Jung Kim, Katsura Emoto, Ryutaro Kawano, Kohei Nakamura, Hideyuki Hayashi, Hatsuyo Takaoka, Akihiko Ogata, Katsuhito Kinoshita, Fumimaro Ito, Lisa Shigematsu, Masahiko Okada, Takahiro Fukushima, Akifumi Mitsuishi, Taro Shino Cancer Medicine.2024;[Epub] CrossRef
Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non-Small Cell Lung Cancer: Implications for Precision Medicine Yurimi Lee, Boram Lee, Yoon-La Choi, Dong-Wook Kang, Joungho Han Modern Pathology.2024; : 100490. CrossRef
FACILITATE: A real-world, multicenter, prospective study investigating the utility of a rapid, fully automated real-time PCR assay versus local reference methods for detecting epidermal growth factor receptor variants in NSCLC Anke Behnke, Anne Cayre, Giovanna De Maglio, Giuseppe Giannini, Lionel Habran, Marina Tarsitano, Massimiliano Chetta, David Cappellen, Alexandra Lespagnol, Cecile Le Naoures, Gabriella Massazza, Annarita Destro, Irina Bonzheim, Achim Rau, Achim Battmann, Pathology and Oncology Research.2023;[Epub] CrossRef
Problems in the Pathologic Diagnosis of Suspected Lung Cancer Soo Han Kim, Mi-Hyun Kim, Min Ki Lee, Jung Seop Eom Tuberculosis and Respiratory Diseases.2023; 86(3): 176. CrossRef
Mesonephric-like Adenocarcinoma of the Ovary: Clinicopathological and Molecular Characteristics Hyun Hee Koh, Eunhyang Park, Hyun-Soo Kim Diagnostics.2022; 12(2): 326. CrossRef
Alveolar Soft Part Sarcoma of the Uterus: Clinicopathological and Molecular Characteristics Yurimi Lee, Kiyong Na, Ha Young Woo, Hyun-Soo Kim Diagnostics.2022; 12(5): 1102. CrossRef
Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing Jeonghyo Lee, Yeon Bi Han, Hyun Jung Kwon, Song Kook Lee, Hyojin Kim, Jin-Haeng Chung Journal of Pathology and Translational Medicine.2022; 56(5): 249. CrossRef
Biomarker testing of cytology specimens in personalized medicine for lung cancer patients Hyojin Kim, Jin-Haeng Chung Journal of Pathology and Translational Medicine.2022; 56(6): 326. CrossRef
Usefulness of BRAF VE1 immunohistochemistry in non–small cell lung cancers: a multi-institutional study by 15 pathologists in Korea Sunhee Chang, Yoon-La Choi, Hyo Sup Shim, Geon Kook Lee, Seung Yeon Ha Journal of Pathology and Translational Medicine.2022; 56(6): 334. CrossRef
Lung Cancer in Korea Sehhoon Park, Chang-Min Choi, Seung-Sik Hwang, Yoon-La Choi, Hyae Young Kim, Young-Chul Kim, Young Tae Kim, Ho Yun Lee, Si Yeol Song, Myung-Ju Ahn Journal of Thoracic Oncology.2021; 16(12): 1988. CrossRef
The use of biomarkers to guide patient and therapy selection has gained much attention to increase the scope and complexity of targeted therapy options and immunotherapy. Clinical trials provide a basis for discovery of biomarkers, which can then aid in development of new drugs. To that end, samples from cancer patients, including DNA, RNA, protein, and the metabolome isolated from cancer tissues and blood or urine, are analyzed in various ways to identify relevant biomarkers. In conjunction with nucleotide-based, high-throughput, next-generation sequencing techniques, therapy-guided biomarker assays relying on protein-based immunohistochemistry play a pivotal role in cancer care. In this review, we discuss the current knowledge regarding DNA and protein biomarkers for cancer immunotherapy
Citations
Citations to this article as recorded by
Biomarkers for Predicting Response to Personalized Immunotherapy in Gastric Cancer Moonsik Kim, Ji Yun Jeong, An Na Seo Diagnostics.2023; 13(17): 2782. CrossRef
With advances in target therapy, molecular analysis of tumors is routinely required for treatment decisions in patients with advanced non-small cell lung cancer (NSCLC). Liquid biopsy refers to the sampling and analysis of circulating cell-free tumor DNA (ctDNA) in various body fluids, primarily blood. Because the technique is minimally invasive, liquid biopsies are the future in cancer management. Epidermal growth factor receptor (EGFR) ctDNA tests have been performed in routine clinical practice in advanced NSCLC patients to guide tyrosine kinase inhibitor treatment. In the near future, liquid biopsy will be a crucial prognostic, predictive, and diagnostic method in NSCLC. Here we present the current status and future perspectives of liquid biopsy in NSCLC.
Citations
Citations to this article as recorded by
Tailored point-of-care biosensors for liquid biopsy in the field of oncology Sima Singh, Pritam Saha Podder, Matt Russo, Charles Henry, Stefano Cinti Lab on a Chip.2023; 23(1): 44. CrossRef
Emerging role of non-invasive and liquid biopsy biomarkers in pancreatic cancer Akash Bararia, Prosenjeet Chakraborty, Paromita Roy, Bitan Kumar Chattopadhay, Amlan Das, Aniruddha Chatterjee, Nilabja Sikdar World Journal of Gastroenterology.2023; 29(15): 2241. CrossRef
Liquid biopsy in the management of advanced lung cancer: Implementation and practical aspects Gabriela Fernandes, Ana Rodrigues, Cláudia Matos, Fernando Barata, Luís Cirnes, Lurdes Ferreira, José Albino Lopes, Margarida Felizardo, Paula Fidalgo, Ulisses Brito, Bárbara Parente Cancer Treatment and Research Communications.2023; 36: 100725. CrossRef
Tweezer PCR: A Highly Specific Method for Accurate Identification of Low-Abundance Mutations Shanglin Li, Yin Gu, Zhi Geng, Kaiyi Li, Yawei Hu, Qiang Liu, Rongxin Fu, Peng Liu Analytical Chemistry.2023; 95(48): 17679. CrossRef
Mesonephric-like Adenocarcinoma of the Ovary: Clinicopathological and Molecular Characteristics Hyun Hee Koh, Eunhyang Park, Hyun-Soo Kim Diagnostics.2022; 12(2): 326. CrossRef
Alveolar Soft Part Sarcoma of the Uterus: Clinicopathological and Molecular Characteristics Yurimi Lee, Kiyong Na, Ha Young Woo, Hyun-Soo Kim Diagnostics.2022; 12(5): 1102. CrossRef
Exosomal MicroRNA Analyses in Esophageal Squamous Cell Carcinoma Cell Lines Sora Kim, Gwang Ha Kim, Su Jin Park, Chae Hwa Kwon, Hoseok I, Moon Won Lee, Bong Eun Lee Journal of Clinical Medicine.2022; 11(15): 4426. CrossRef
Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee Journal of Pathology and Translational Medicine.2021; 55(3): 181. CrossRef
Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer Pamela Abdayem, David Planchard European Respiratory Review.2021; 30(161): 200294. CrossRef
Dynamics of Specific cfDNA Fragments in the Plasma of Full Marathon Participants Takehito Sugasawa, Shin-ichiro Fujita, Tomoaki Kuji, Noriyo Ishibashi, Kenshirou Tamai, Yasushi Kawakami, Kazuhiro Takekoshi Genes.2021; 12(5): 676. CrossRef
Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC Daniela Ferreira, Juliana Miranda, Paula Martins-Lopes, Filomena Adega, Raquel Chaves International Journal of Molecular Sciences.2021; 22(8): 3815. CrossRef
Real-World Analysis of the EGFR Mutation Test in Tissue and Plasma Samples from Non-Small Cell Lung Cancer Hyunwoo Lee, Joungho Han, Yoon-La Choi Diagnostics.2021; 11(9): 1695. CrossRef
Objective Quantitation of EGFR Protein Levels using Quantitative Dot Blot Method for the Prognosis of Gastric Cancer Patients Lei Xin, Fangrong Tang, Bo Song, Maozhou Yang, Jiandi Zhang Journal of Gastric Cancer.2021; 21(4): 335. CrossRef
The Role of the Liquid Biopsy in Decision-Making for Patients with Non-Small Cell Lung Cancer D. Akhoundova, J. Mosquera Martinez, L. E. Musmann, C. Britschgi, C. Rütsche, M. Rechsteiner, E. Nadal, M. R. Garcia Campelo, A. Curioni-Fontecedro Journal of Clinical Medicine.2020; 9(11): 3674. CrossRef
Expanding opportunities in precision oncology T Raja Cancer Research, Statistics, and Treatment.2020; 3(4): 863. CrossRef
Remarkable developments in immuno-oncology have changed the landscape of gastric cancer (GC) treatment. Because immunotherapy intervenes with tumor immune response rather than directly targeting tumor cells, it is important to develop a greater understanding of tumor immunity. This review paper summarizes the tumor immune reaction and immune escape mechanisms while focusing on the role of T cells and their co-inhibitory signals, such as the immune checkpoint molecules programmed death-1 and programmed deathligand 1 (PD-L1). This paper also describes past clinical trials of immunotherapy for patients with GC and details their clinical implications. Strong predictive markers are essential to improve response to immunotherapy. Microsatellite instability, Epstein-Barr virus, PD-L1 expression, and tumor mutational burden are now regarded as potent predictive markers for immunotherapy in patients with GC. Novel immunotherapy and combination therapy targeting new immune checkpoint molecules such as lymphocyte-activation gene 3, T cell immunoglobulin, and mucin domain containing-3, and indoleamine 2,3-dioxygenase have been suggested, and trials are ongoing to evaluate their safety and efficacy. Immunotherapy is an important treatment option for patients with GC and has great potential for improving patient outcome, and further research in immuno-oncology should be carried out.
Citations
Citations to this article as recorded by
Ubiquilin-4 induces immune escape in gastric cancer by activating the notch signaling pathway Quan Jiang, Hao Chen, Shixin Zhou, Tao Zhu, Wenshuai Liu, Hao Wu, Yong Zhang, Fenglin Liu, Yihong Sun Cellular Oncology.2024; 47(1): 303. CrossRef
Expression and prognostic value of APOBEC2 in gastric adenocarcinoma and its association with tumor-infiltrating immune cells Lipan Wei, Xiuqian Wu, Lan Wang, Ling Chen, Xuejun Wu, Tiantian Song, Yuanyuan Wang, Wenjun Chang, Aizhen Guo, Yongdong Niu, Haihua Huang BMC Cancer.2024;[Epub] CrossRef
Identification and characterization of CLEC11A and its derived immune signature in gastric cancer Qing Zheng, Zhenqi Gong, Baizhi Li, Runzi Cheng, Weican Luo, Cong Huang, Huaiming Wang Frontiers in Immunology.2024;[Epub] CrossRef
Computed tomography-detected extramural venous invasion-related gene signature: a potential negative biomarker of immune checkpoint inhibitor treatment in patients with gastric cancer Hao Yang, Xinyi Gou, Caizhen Feng, Yinli Zhang, Fan Chai, Nan Hong, Yingjiang Ye, Yi Wang, Bo Gao, Jin Cheng Journal of Translational Medicine.2023;[Epub] CrossRef
A standardized pathology report for gastric cancer: 2nd edition Young Soo Park, Myeong-Cherl Kook, Baek-hui Kim, Hye Seung Lee, Dong-Wook Kang, Mi-Jin Gu, Ok Ran Shin, Younghee Choi, Wonae Lee, Hyunki Kim, In Hye Song, Kyoung-Mee Kim, Hee Sung Kim, Guhyun Kang, Do Youn Park, So-Young Jin, Joon Mee Kim, Yoon Jung Choi, Journal of Pathology and Translational Medicine.2023; 57(1): 1. CrossRef
A Standardized Pathology Report for Gastric Cancer: 2nd Edition Young Soo Park, Myeong-Cherl Kook, Baek-hui Kim, Hye Seung Lee, Dong-Wook Kang, Mi-Jin Gu, Ok Ran Shin, Younghee Choi, Wonae Lee, Hyunki Kim, In Hye Song, Kyoung-Mee Kim, Hee Sung Kim, Guhyun Kang, Do Youn Park, So-Young Jin, Joon Mee Kim, Yoon Jung Choi, Journal of Gastric Cancer.2023; 23(1): 107. CrossRef
Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach Tae-Han Kim, In-Ho Kim, Seung Joo Kang, Miyoung Choi, Baek-Hui Kim, Bang Wool Eom, Bum Jun Kim, Byung-Hoon Min, Chang In Choi, Cheol Min Shin, Chung Hyun Tae, Chung sik Gong, Dong Jin Kim, Arthur Eung-Hyuck Cho, Eun Jeong Gong, Geum Jong Song, Hyeon-Su Im Journal of Gastric Cancer.2023; 23(1): 3. CrossRef
Could Toll-like Receptor 2 Serve as Biomarker to Detect Advanced Gastric Cancer? Marek Majewski, Kamil Torres, Paulina Mertowska, Sebastian Mertowski, Izabela Korona-Głowniak, Jan Korulczyk, Witold Zgodziński, Ewelina Grywalska International Journal of Molecular Sciences.2023; 24(6): 5824. CrossRef
Research Progress of Immunotherapy for Gastric Cancer Zhipeng Zhang, Ningning Liu, Mingyu Sun Technology in Cancer Research & Treatment.2023; 22: 153303382211505. CrossRef
Case Report: A rare synchronous multiple gastric carcinoma achieved progression-free disease through NGS-guided serial treatment Xinyi Shao, Jin Yin, Di Wang, Erjiong Huang, Yini Zhang, Jiani C. Yin, Chen Huang, Hao Wu, Xiaoli Wu Frontiers in Oncology.2023;[Epub] CrossRef
Artificial Intelligence-Enabled Gastric Cancer Interpretations Mustafa Yousif, Liron Pantanowitz Surgical Pathology Clinics.2023; 16(4): 673. CrossRef
The Optimal Tumor Mutational Burden Cutoff Value as a Novel Marker for Predicting the Efficacy of Programmed Cell Death-1 Checkpoint Inhibitors in Advanced Gastric Cancer Jae Yeon Jang, Youngkyung Jeon, Sun Young Jeong, Sung Hee Lim, Won Ki Kang, Jeeyun Lee, Seung Tae Kim Journal of Gastric Cancer.2023; 23(3): 476. CrossRef
Biomarkers for Predicting Response to Personalized Immunotherapy in Gastric Cancer Moonsik Kim, Ji Yun Jeong, An Na Seo Diagnostics.2023; 13(17): 2782. CrossRef
The Prognostic Value of the Prognostic Nutritional Index in Patients with Advanced or Metastatic Gastric Cancer Treated with Immunotherapy Yuting Pan, Yue Ma, Guanghai Dai Nutrients.2023; 15(19): 4290. CrossRef
Molecular classification of gastric cancer predicts survival in patients undergoing radical gastrectomy based on project HOPE Kenichiro Furukawa, Keiichi Hatakeyama, Masanori Terashima, Takeshi Nagashima, Kenichi Urakami, Keiichi Ohshima, Akifumi Notsu, Takashi Sugino, Taisuke Yagi, Keiichi Fujiya, Satoshi Kamiya, Makoto Hikage, Yutaka Tanizawa, Etsuro Bando, Yae Kanai, Yasuto A Gastric Cancer.2022; 25(1): 138. CrossRef
Immunotherapy for gastric cancer: a 2021 update Christo Kole, Nikolaos Charalampakis, Sergios Tsakatikas, Nikolaos-Iasonas Kouris, George Papaxoinis, Michalis V Karamouzis, Anna Koumarianou, Dimitrios Schizas Immunotherapy.2022; 14(1): 41. CrossRef
The immune microenvironment in gastric adenocarcinoma Yana Zavros, Juanita L. Merchant Nature Reviews Gastroenterology & Hepatology.2022; 19(7): 451. CrossRef
Immunomodulation by Gut Microbiome on Gastrointestinal Cancers: Focusing on Colorectal Cancer Raghad Khalid AL-Ishaq, Lenka Koklesova, Peter Kubatka, Dietrich Büsselberg Cancers.2022; 14(9): 2140. CrossRef
An Immunity-Associated lncRNA Signature for Predicting Prognosis in Gastric Adenocarcinoma Xiaowen Zhao, Pingfan Wu, Dongling Liu, Changtian Li, Ling Xue, Zhe Liu, Meng Zhu, Jie Yang, Ziyi Chen, Yaling Li, Yali She, Kathiravan Srinivasan Journal of Healthcare Engineering.2022; 2022: 1. CrossRef
RNA modification writers influence tumor microenvironment in gastric cancer and prospects of targeted drug therapy Peng Song, Sheng Zhou, Xiaoyang Qi, Yuwen Jiao, Yu Gong, Jie Zhao, Haojun Yang, Zhifen Qian, Jun Qian, Liming Tang Journal of Bioinformatics and Computational Biology.2022;[Epub] CrossRef
Identification of the three subtypes and the prognostic characteristics of stomach adenocarcinoma: analysis of the hypoxia-related long non-coding RNAs Zehua Fan, Yanqun Wang, Rong Niu Functional & Integrative Genomics.2022; 22(5): 919. CrossRef
Complete Response of High Microsatellite Instability Gastric Cancer and Synchronous Microsatellite Stability Rectal Cancer Zachary E Hunzeker, Pooja Bhakta, Sindusha R Gudipally, Sri Bharathi Kavuri, Rohit Venkatesan, Chukwuyejulumafor Nwanze Cureus.2022;[Epub] CrossRef
Immune Profiling in Gastric Cancer Reveals the Dynamic Landscape of Immune Signature Underlying Tumor Progression Yuhan Wei, Jianwei Zhang, Xueke Fan, Zhi Zheng, Xiaoyue Jiang, Dexi Chen, Yuting Lu, Yingrui Li, Miao Wang, Min Hu, Qi Du, Liuting Yang, Hongzhong Li, Yi Xiao, Yongfu Li, Jiangtao Jin, Deying Wang, Xiangliang Yuan, Qin Li Frontiers in Immunology.2022;[Epub] CrossRef
Tumor vessel normalization and immunotherapy in gastric cancer Xianzhe Yu, Shan He, Jian Shen, Qiushi Huang, Peng Yang, Lin Huang, Dan Pu, Li Wang, Lu Li, Jinghua Liu, Zelong Liu, Lingling Zhu Therapeutic Advances in Medical Oncology.2022; 14: 175883592211101. CrossRef
FN1 is a prognostic biomarker and correlated with immune infiltrates in gastric cancers Han Wang, Junchang Zhang, Huan Li, Hong Yu, Songyao Chen, Shuhao Liu, Changhua Zhang, Yulong He Frontiers in Oncology.2022;[Epub] CrossRef
Molecular Pathology of Gastric Cancer Moonsik Kim, An Na Seo Journal of Gastric Cancer.2022; 22(4): 264. CrossRef
Bioinformatics Analysis and Structure of Gastric Cancer Prognosis Model Based on Lipid Metabolism and Immune Microenvironment Yongzhi Chen, Hongjun Yuan, Qian Yu, Jianyu Pang, Miaomiao Sheng, Wenru Tang Genes.2022; 13(9): 1581. CrossRef
Clinical implications of interleukins-31, 32, and 33 in gastric cancer Qing-Hua Liu, Ji-Wei Zhang, Lei Xia, Steven G Wise, Brett David Hambly, Kun Tao, Shi-San Bao World Journal of Gastrointestinal Oncology.2022; 14(9): 1808. CrossRef
Microbiota and the Immune System—Actors in the Gastric Cancer Story Marek Majewski, Paulina Mertowska, Sebastian Mertowski, Konrad Smolak, Ewelina Grywalska, Kamil Torres Cancers.2022; 14(15): 3832. CrossRef
Bioinformatics and Experimental Analyses Reveal MAP4K4 as a Potential Marker for Gastric Cancer Junping Zhang, Xiaoping Cai, Weifeng Cui, Zheng Wei Genes.2022; 13(10): 1786. CrossRef
Common strategies for effective immunotherapy of gastroesophageal cancers using immune checkpoint inhibitors Shuang Ma, Fei Chen Pathology - Research and Practice.2022; 238: 154110. CrossRef
High-level of intratumoral GITR+ CD4 T cells associate with poor prognosis in gastric cancer Shouyu Ke, Feng Xie, Yixian Guo, Jieqiong Chen, Zeyu Wang, Yimeng Yu, Haigang Geng, Danhua Xu, Xu Liu, Xiang Xia, Fengrong Yu, Chunchao Zhu, Zizhen Zhang, Gang Zhao, Bin Li, Wenyi Zhao iScience.2022; 25(12): 105529. CrossRef
Characteristics of Adenosine-to-Inosine RNA editing-based subtypes and novel risk score for the prognosis and drug sensitivity in stomach adenocarcinoma Jingjing Pan, Xinyuan Gu, Jing Luo, Xinye Qian, Qiang Gao, Tianjie Li, Longying Ye, Chenlu Li Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
Inhibition of NF‐κB is required for oleanolic acid to downregulate PD‐L1 by promoting DNA demethylation in gastric cancer cells Xirong Lu, Yuyi Li, Wei Yang, Minghao Tao, Yanmiao Dai, Jinkang Xu, Qianfei Xu Journal of Biochemical and Molecular Toxicology.2021;[Epub] CrossRef
Prognostic Value of C-Reactive Protein to Albumin Ratio in Gastric Cancer: A Meta-Analysis Liang Yue, Yi Lu, Yulin Li, Yilin Wang Nutrition and Cancer.2021; 73(10): 1864. CrossRef
Immunogenic characteristics of microsatellite instability‐low esophagogastric junction adenocarcinoma based on clinicopathological, molecular, immunological and survival analyses Yu Imamura, Tasuku Toihata, Ikumi Haraguchi, Yoko Ogata, Manabu Takamatsu, Aya Kuchiba, Norio Tanaka, Osamu Gotoh, Seiichi Mori, Yuichiro Nakashima, Eiji Oki, Masaki Mori, Yoshinao Oda, Kenichi Taguchi, Manabu Yamamoto, Masaru Morita, Naoya Yoshida, Hideo International Journal of Cancer.2021; 148(5): 1260. CrossRef
Two Similar Signatures for Predicting the Prognosis and Immunotherapy Efficacy of Stomach Adenocarcinoma Patients Taohua Yue, Shuai Zuo, Jing Zhu, Shihao Guo, Zhihao Huang, Jichang Li, Xin Wang, Yucun Liu, Shanwen Chen, Pengyuan Wang Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
Tumor microenvironment characterization in stage IV gastric cancer Feng Yang, Zhenbao Wang, Xianxue Zhang Bioscience Reports.2021;[Epub] CrossRef
E2F2 inhibition induces autophagy via the PI3K/Akt/mTOR pathway in gastric cancer Hui Li, Shufen Zhao, Liwei Shen, Peige Wang, Shihai Liu, Yingji Ma, Zhiwei Liang, Gongjun Wang, Jing Lv, Wensheng Qiu Aging.2021; 13(10): 13626. CrossRef
Chemoradiation induces upregulation of immunogenic cell death-related molecules together with increased expression of PD-L1 and galectin-9 in gastric cancer S. H. Petersen, L. F. Kua, S. Nakajima, W. P. Yong, K. Kono Scientific Reports.2021;[Epub] CrossRef
Establishment of an Immune Cell Infiltration Score to Help Predict the Prognosis and Chemotherapy Responsiveness of Gastric Cancer Patients Quan Jiang, Jie Sun, Hao Chen, Chen Ding, Zhaoqing Tang, Yuanyuan Ruan, Fenglin Liu, Yihong Sun Frontiers in Oncology.2021;[Epub] CrossRef
Microsatellite instability in Gastric Cancer: Between lights and shadows Elisabetta Puliga, Simona Corso, Filippo Pietrantonio, Silvia Giordano Cancer Treatment Reviews.2021; 95: 102175. CrossRef
Survival-associated alternative splicing events interact with the immune microenvironment in stomach adenocarcinoma Zai-Sheng Ye, Miao Zheng, Qin-Ying Liu, Yi Zeng, Sheng-Hong Wei, Yi Wang, Zhi-Tao Lin, Chen Shu, Qiu-Hong Zheng, Lu-Chuan Chen World Journal of Gastroenterology.2021; 27(21): 2871. CrossRef
Immunotherapy of gastric cancer: Past, future perspective and challenges Jun Xie, Liping Fu, Li Jin Pathology - Research and Practice.2021; 218: 153322. CrossRef
Clinicopathologic and Prognostic Association of GRP94 Expression in Colorectal Cancer with Synchronous and Metachronous Metastases Sumi Yun, Sukmook Lee, Ho-Young Lee, Hyeon Jeong Oh, Yoonjin Kwak, Hye Seung Lee International Journal of Molecular Sciences.2021; 22(13): 7042. CrossRef
Injectable shear-thinning polylysine hydrogels for localized immunotherapy of gastric cancer through repolarization of tumor-associated macrophages Yan Yang, Yang Yang, Meili Chen, Jianquan Chen, Jinyan Wang, Yajun Ma, Hanqing Qian Biomaterials Science.2021; 9(19): 6597. CrossRef
Correlation between LRP1B Mutations and Tumor Mutation Burden in Gastric Cancer Sizhe Hu, Xiaokang Zhao, Feng Qian, Cancan Jin, Kaishun Hou, Tao Huang Computational and Mathematical Methods in Medicine.2021; 2021: 1. CrossRef
Comprehensive Analysis to Identify MAGEA3 Expression Correlated With Immune Infiltrates and Lymph Node Metastasis in Gastric Cancer Jinji Jin, Jianxin Tu, Jiahuan Ren, Yiqi Cai, Wenjing Chen, Lifang Zhang, Qiyu Zhang, Guanbao Zhu Frontiers in Oncology.2021;[Epub] CrossRef
Effect of P2X7 receptor on tumorigenesis and its pharmacological properties Wen-jun Zhang, Ce-gui Hu, Zheng-ming Zhu, Hong-liang Luo Biomedicine & Pharmacotherapy.2020; 125: 109844. CrossRef
Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer Byung Woog Kang, Ian Chau ESMO Open.2020; 5(4): e000791. CrossRef
Is ramucirumab still the only second-line treatment in metastatic gastric cancer? Khalil El Gharib, Hampig Raphael Kourie Pharmacogenomics.2020; 21(17): 1203. CrossRef
Deep Learning Predicts Underlying Features on Pathology Images with Therapeutic Relevance for Breast and Gastric Cancer Renan Valieris, Lucas Amaro, Cynthia Aparecida Bueno de Toledo Osório, Adriana Passos Bueno, Rafael Andres Rosales Mitrowsky, Dirce Maria Carraro, Diana Noronha Nunes, Emmanuel Dias-Neto, Israel Tojal da Silva Cancers.2020; 12(12): 3687. CrossRef
Background SMAD family member 4 (SMAD4) has gained attention as a promising prognostic factor of colorectal cancer (CRC) as well as a key molecule to understand the tumorigenesis and progression of CRC.
Methods We retrospectively analyzed 1,281 CRC cases immunohistochemically for their expression status of SMAD4, and correlated this status with clinicopathologic and molecular features of CRCs.
Results A loss of nuclear SMAD4 was significantly associated with frequent lymphovascular and perineural invasion, tumor budding, fewer tumor-infiltrating lymphocytes, higher pT and pN category, and frequent distant metastasis. In contrast, tumors overexpressing SMAD4 showed a significant association with sporadic microsatellite instability. After adjustment for TNM stage, tumor differentiation, adjuvant chemotherapy, and lymphovascular invasion, the loss of SMAD4 was found to be an independent prognostic factor for worse 5-year progression-free survival (hazard ratio [HR], 1.27; 95% confidence interval [CI], 1.01 to 1.60; p=.042) and 7-year cancerspecific survival (HR, 1.45; 95% CI, 1.06 to 1.99; p=.022).
Conclusions We confirmed the value of determining the loss of SMAD4 immunohistochemically as an independent prognostic factor for CRC in general. In addition, we identified some histologic and molecular features that might be clues to elucidate the role of SMAD4 in colorectal tumorigenesis and progression.
Citations
Citations to this article as recorded by
Unraveling Resistance to Immunotherapy in MSI-High Colorectal Cancer Ronald Heregger, Florian Huemer, Markus Steiner, Alejandra Gonzalez-Martinez, Richard Greil, Lukas Weiss Cancers.2023; 15(20): 5090. CrossRef
Association of β-Catenin, APC, SMAD3/4, Tp53, and Cyclin D1 Genes in Colorectal Cancer: A Systematic Review and Meta-Analysis Hongfeng Yan, Fuquan Jiang, Jianwu Yang, Ying-Kun Xu Genetics Research.2022; 2022: 1. CrossRef
Comprehensive genetic features of gastric mixed adenoneuroendocrine carcinomas and pure neuroendocrine carcinomas Jiwon Koh, Soo Kyung Nam, Yoonjin Kwak, Gilhyang Kim, Ka‐Kyung Kim, Byung‐Chul Lee, Sang‐Hoon Ahn, Do Joong Park, Hyung‐Ho Kim, Kyoung Un Park, Woo Ho Kim, Hye Seung Lee The Journal of Pathology.2021; 253(1): 94. CrossRef
Alterations of PTEN and SMAD4 methylation in diagnosis of breast cancer: implications of methyl II PCR assay Menha Swellam, Entsar A. Saad, Shimaa Sabry, Adel Denewer, Camelia Abdel Malak, Amr Abouzid Journal of Genetic Engineering and Biotechnology.2021; 19(1): 54. CrossRef
Molecular Characterization and Functional Analysis of Two Steroidogenic Genes TSPO and SMAD4 in Yellow Catfish Fang Chen, Chong-Chao Zhong, Chang-Chun Song, Shu-Wei Chen, Yang He, Xiao-Ying Tan International Journal of Molecular Sciences.2021; 22(9): 4505. CrossRef
SMAD7 and SMAD4 expression in colorectal cancer progression and therapy response Jovana Rosic, Sandra Dragicevic, Marko Miladinov, Jovana Despotovic, Aleksandar Bogdanovic, Zoran Krivokapic, Aleksandra Nikolic Experimental and Molecular Pathology.2021; 123: 104714. CrossRef
Actionable Potentials of Less Frequently Mutated Genes in Colorectal Cancer and Their Roles in Precision Medicine Ryia Illani Mohd Yunos, Nurul Syakima Ab Mutalib, Francis Yew Fu Tieng, Nadiah Abu, Rahman Jamal Biomolecules.2020; 10(3): 476. CrossRef
Blockade of the programmed cell death-1 (PD-1) axis has already been established as an effective treatment of non-small cell lung cancer. Immunohistochemistry (IHC) for programmed death-ligand 1 (PD-L1) protein is the only available biomarker that can guide treatment with immune checkpoint inhibitors in non-small cell lung cancer. Because each PD-1/PD-L1 blockade was approved together with a specific PD-L1 IHC assay used in the clinical trials, pathologists have been challenged with performing various assays with a limited sample. To provide a more unified understanding of this, several cross-validation studies between platforms have been performed and showed consistent results. However, the interchangeability of assays may be limited in practice because of the risk of misclassification of patients for the treatment. Furthermore, several issues, including the temporal and spatial heterogeneity of PD-L1 expression in the tumor, and the potential for cytology specimens to be used as an alternative to tissue samples for PD-L1 testing, have still not been resolved. In the future, one of the main aims of immunotherapy research should be to find a novel predictive biomarker for PD-1 blockade therapy and a way to combine it with PD-L1 IHC and other tests.
Citations
Citations to this article as recorded by
Precision Oncology in Lung Cancer Surgery Patrick Bou-Samra, Sunil Singhal Surgical Oncology Clinics of North America.2024; 33(2): 311. CrossRef
Expression of PD-L1 clones (22C3 and 28-8) in hepatocellular carcinoma: a tertiary cancer care hospital experience Kashif Asghar, Shaarif Bashir, Muhammad Hassan, Asim Farooq, Muhammad Abu Bakar, Sundus Bilal, Maryam Hameed, Shafqat Mehmood, Asif Loya Egyptian Liver Journal.2024;[Epub] CrossRef
Engineering Proteus mirabilis improves antitumor efficacy via enhancing cytotoxic T cell responses Hong Zhang, Yinlin Luo, Xincheng Zhao, Xiande Liu Molecular Therapy: Oncology.2024; 32(1): 200770. CrossRef
Unlocking the potential of oncology biomarkers: advancements in clinical theranostics Ankit Kumar Dubey, Ishnoor Kaur, Reecha Madaan, Shikha Raheja, Rajni Bala, Manoj Garg, Suresh Kumar, Viney Lather, Vineet Mittal, Deepti Pandita, Rohit Gundamaraju, Rajeev K. Singla, Rohit Sharma Drug Metabolism and Personalized Therapy.2024; 39(1): 5. CrossRef
Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non–small cell lung cancer Uiju Cho, Soyoung Im, Hyung Soon Park Journal of Pathology and Translational Medicine.2024; 58(2): 49. CrossRef
Predicting efficacy assessment of combined treatment of radiotherapy and nivolumab for NSCLC patients through virtual clinical trials using QSP modeling Miriam Schirru, Hamza Charef, Khalil-Elmehdi Ismaili, Frédérique Fenneteau, Didier Zugaj, Pierre-Olivier Tremblay, Fahima Nekka Journal of Pharmacokinetics and Pharmacodynamics.2024;[Epub] CrossRef
Predictions of PD-L1 Expression Based on CT Imaging Features in Lung Squamous Cell Carcinoma Seong Hee Yeo, Hyun Jung Yoon, Injoong Kim, Yeo Jin Kim, Young Lee, Yoon Ki Cha, So Hyeon Bak Journal of the Korean Society of Radiology.2024; 85(2): 394. CrossRef
Special issue “The advance of solid tumor research in China”: FGFR4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer Guanghui Gao, Longgang Cui, Fei Zhou, Tao Jiang, Wanying Wang, Shiqi Mao, Fengying Wu, Fangli Jiang, Bei Zhang, Ting Bei, Wenchuan Xie, Cheng Zhang, Hougang Zhang, Chan Gao, Xiaochen Zhao, Yuezong Bai, Caicun Zhou, Shengxiang Ren International Journal of Cancer.2023; 152(1): 79. CrossRef
Molecular Classification of Extrapulmonary Neuroendocrine Carcinomas With Emphasis on POU2F3-positive Tuft Cell Carcinoma Jiwon Koh, Haeryoung Kim, Kyung Chul Moon, Cheol Lee, Kyoungbun Lee, Han Suk Ryu, Kyeong Cheon Jung, Yoon Kyung Jeon American Journal of Surgical Pathology.2023; 47(2): 183. CrossRef
Biomarkers for Predicting Response to Personalized Immunotherapy in Gastric Cancer Moonsik Kim, Ji Yun Jeong, An Na Seo Diagnostics.2023; 13(17): 2782. CrossRef
PD-L1 Expression in Pituitary Neuroendocrine Tumors/Pituitary Adenomas Giulia Cossu, Stefano La Rosa, Jean Philippe Brouland, Nelly Pitteloud, Ethan Harel, Federico Santoni, Maxime Brunner, Roy Thomas Daniel, Mahmoud Messerer Cancers.2023; 15(18): 4471. CrossRef
Prognostic Significance of Programmed Cell Death Ligand 1 Expression in High-Grade Serous Ovarian Carcinoma: A Systematic Review and Meta-Analysis Jeongwan Kang, Kang Min Han, Hera Jung, Hyunchul Kim Diagnostics.2023; 13(20): 3258. CrossRef
A targeted expression panel for classification, gene fusion detection and PD-L1 measurements – Can molecular profiling replace immunohistochemistry in non-small cell lung cancer? Anita Tranberg Simonsen, Amalie Utke, Johanne Lade-Keller, Lasse Westphal Thomsen, Torben Steiniche, Magnus Stougaard Experimental and Molecular Pathology.2022; 125: 104749. CrossRef
Program death ligand‐1 immunocytochemistry in lung cancer cytological samples: A systematic review Swati Satturwar, Ilaria Girolami, Enrico Munari, Francesco Ciompi, Albino Eccher, Liron Pantanowitz Diagnostic Cytopathology.2022; 50(6): 313. CrossRef
Computer-assisted three-dimensional quantitation of programmed death-ligand 1 in non-small cell lung cancer using tissue clearing technology Yen-Yu Lin, Lei-Chi Wang, Yu-Han Hsieh, Yu-Ling Hung, Yung-An Chen, Yu-Chieh Lin, Yen-Yin Lin, Teh-Ying Chou Journal of Translational Medicine.2022;[Epub] CrossRef
Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer Cristina-Florina Pirlog, Horia Teodor Cotan, Andreea Parosanu, Cristina Orlov Slavu, Ana Maria Popa, Cristian Iaciu, Mihaela Olaru, Alexandru Vlad Oprita, Irina Nita, Cornelia Nitipir Cureus.2022;[Epub] CrossRef
Expert opinion on NSCLC small specimen biomarker testing — Part 2: Analysis, reporting, and quality assessment Frédérique Penault-Llorca, Keith M. Kerr, Pilar Garrido, Erik Thunnissen, Elisabeth Dequeker, Nicola Normanno, Simon J. Patton, Jenni Fairley, Joshua Kapp, Daniëlle de Ridder, Aleš Ryška, Holger Moch Virchows Archiv.2022; 481(3): 351. CrossRef
Novel Inflammasome-Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early-Stage Non-Small Cell Lung Cancer Chih-Cheng Tsao, Hsin-Hung Wu, Ying-Fu Wang, Po-Chien Shen, Wen-Ting Wu, Huang-Yun Chen, Yang-Hong Dai Biomedicines.2022; 10(7): 1539. CrossRef
Comparative Analysis of Mutation Status and Immune Landscape for Squamous Cell Carcinomas at Different Anatomical sites Wenqi Ti, Tianhui Wei, Jianbo Wang, Yufeng Cheng Frontiers in Immunology.2022;[Epub] CrossRef
Pan-cancer analysis of the angiotensin II receptor-associated protein as a prognostic and immunological gene predicting immunotherapy responses in pan-cancer Kai Hong, Yingjue Zhang, Lingli Yao, Jiabo Zhang, Xianneng Sheng, Lihua Song, Yu Guo, Yangyang Guo Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
Molecular imaging of immune checkpoints in oncology: Current and future applications Shushan Ge, Tongtong Jia, Jihui Li, Bin Zhang, Shengming Deng, Shibiao Sang Cancer Letters.2022; 548: 215896. CrossRef
PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma Katerina Hadrava Vanova, Ondrej Uher, Leah Meuter, Suman Ghosal, Sara Talvacchio, Mayank Patel, Jiri Neuzil, Karel Pacak Frontiers in Oncology.2022;[Epub] CrossRef
Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art Nicoletta Provinciali, Marco Greppi, Silvia Pesce, Mariangela Rutigliani, Irene Maria Briata, Tania Buttiron Webber, Marianna Fava, Andrea DeCensi, Emanuela Marcenaro Frontiers in Immunology.2022;[Epub] CrossRef
PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours John Turchini, Loretta Sioson, Adele Clarkson, Amy Sheen, Anthony J. Gill Endocrine Pathology.2021; 32(3): 408. CrossRef
Comprehensive tumor molecular profile analysis in clinical practice Mustafa Özdoğan, Eirini Papadopoulou, Nikolaos Tsoulos, Aikaterini Tsantikidi, Vasiliki-Metaxa Mariatou, Georgios Tsaousis, Evgenia Kapeni, Evgenia Bourkoula, Dimitrios Fotiou, Georgios Kapetsis, Ioannis Boukovinas, Nikolaos Touroutoglou, Athanasios Fassa BMC Medical Genomics.2021;[Epub] CrossRef
CT-Based Hand-crafted Radiomic Signatures Can Predict PD-L1 Expression Levels in Non-small Cell Lung Cancer: a Two-Center Study Zekun Jiang, Yinjun Dong, Linke Yang, Yunhong Lv, Shuai Dong, Shuanghu Yuan, Dengwang Li, Liheng Liu Journal of Digital Imaging.2021; 34(5): 1073. CrossRef
Deep Learning of Histopathological Features for the Prediction of Tumour Molecular Genetics Pierre Murchan, Cathal Ó’Brien, Shane O’Connell, Ciara S. McNevin, Anne-Marie Baird, Orla Sheils, Pilib Ó Broin, Stephen P. Finn Diagnostics.2021; 11(8): 1406. CrossRef
Molecular Imaging and the PD-L1 Pathway: From Bench to Clinic David Leung, Samuel Bonacorsi, Ralph Adam Smith, Wolfgang Weber, Wendy Hayes Frontiers in Oncology.2021;[Epub] CrossRef
A comparative study of immunotherapy as second-line treatment and beyond in patients with advanced non-small-cell lung carcinoma Jerónimo Rafael Rodríguez-Cid, Sonia Carrasco-Cara Chards, Iván Romarico González-Espinoza, Vanessa García-Montes, Julio César Garibay-Díaz, Osvaldo Hernández-Flores, Rodrigo Riera-Sala, Anna Gozalishvili-Boncheva, Jorge Arturo Alatorre-Alexander, Luis Ma Lung Cancer Management.2021;[Epub] CrossRef
Clinical utility of the C‐reactive protein:albumin ratio in non‐small cell lung cancer patients treated with nivolumab Taisuke Araki, Kazunari Tateishi, Kei Sonehara, Shuko Hirota, Masamichi Komatsu, Manabu Yamamoto, Shintaro Kanda, Hiroshi Kuraishi, Masayuki Hanaoka, Tomonobu Koizumi Thoracic Cancer.2021; 12(5): 603. CrossRef
Programmed Cell Death Ligand 1-Transfected Mouse Bone Marrow Mesenchymal Stem Cells as Targeted Therapy for Rheumatoid Arthritis Qiong-ying Hu, Yun Yuan, Yu-chen Li, Lu-yao Yang, Xiang-yu Zhou, Da-qian Xiong, Zi-yi Zhao, Hiroshi Tanaka BioMed Research International.2021; 2021: 1. CrossRef
PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study Belen Rubio-Viqueira, Margarita Majem Tarruella, Martín Lázaro, Sergio Vázquez Estévez, Juan Felipe Córdoba-Ortega, Inmaculada Maestu Maiques, Jorge García González, Ana Blasco Cordellat, Javier Valdivia-Bautista, Carmen González Arenas, Jose Miguel Sánch Lung Cancer Management.2021;[Epub] CrossRef
Can Systems Biology Advance Clinical Precision Oncology? Andrea Rocca, Boris N. Kholodenko Cancers.2021; 13(24): 6312. CrossRef
Do we need PD‐L1 as a biomarker for thyroid cytologic and histologic specimens? Marc P. Pusztaszeri, Massimo Bongiovanni, Fadi Brimo Cancer Cytopathology.2020; 128(3): 160. CrossRef
Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment Andrea Botticelli, Pamela Vernocchi, Federico Marini, Andrea Quagliariello, Bruna Cerbelli, Sofia Reddel, Federica Del Chierico, Francesca Di Pietro, Raffaele Giusti, Alberta Tomassini, Ottavia Giampaoli, Alfredo Miccheli, Ilaria Grazia Zizzari, Marianna Journal of Translational Medicine.2020;[Epub] CrossRef
Immune checkpoint inhibitors in advanced non–small cell lung cancer: A metacentric experience from India Santosh Kumar, Srujana Joga, Bivas Biswas, Deepak Dabkara, Kuruswamy Thurai Prasad, Navneet Singh, Prabhat Singh Malik, Sachin Khurana, Sandip Ganguly, Valliappan Muthu, Ullas Batra Current Problems in Cancer.2020; 44(3): 100549. CrossRef
Utility of CT radiomics for prediction of PD‐L1 expression in advanced lung adenocarcinomas Jiyoung Yoon, Young Joo Suh, Kyunghwa Han, Hyoun Cho, Hye‐Jeong Lee, Jin Hur, Byoung Wook Choi Thoracic Cancer.2020; 11(4): 993. CrossRef
Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm Lars H. Breimer, Petros Nousios, Louise Olsson, Hans Brunnström Scandinavian Journal of Clinical and Laboratory Investigation.2020; 80(5): 360. CrossRef
Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts Jean-David Fumet, Caroline Truntzer, Mark Yarchoan, Francois Ghiringhelli European Journal of Cancer.2020; 131: 40. CrossRef
Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient Giovanni Rossi, Alessandro Russo, Marco Tagliamento, Alessandro Tuzi, Olga Nigro, Giacomo Vallome, Claudio Sini, Massimiliano Grassi, Maria Giovanna Dal Bello, Simona Coco, Luca Longo, Lodovica Zullo, Enrica Teresa Tanda, Chiara Dellepiane, Paolo Pronzato Cancers.2020; 12(5): 1125. CrossRef
Current status and future perspectives of liquid biopsy in non-small cell lung cancer Sunhee Chang, Jae Young Hur, Yoon-La Choi, Chang Hun Lee, Wan Seop Kim Journal of Pathology and Translational Medicine.2020; 54(3): 204. CrossRef
Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record Fabio Pagni, Umberto Malapelle, Claudio Doglioni, Gabriella Fontanini, Filippo Fraggetta, Paolo Graziano, Antonio Marchetti, Elena Guerini Rocco, Pasquale Pisapia, Elena V. Vigliar, Fiamma Buttitta, Marta Jaconi, Nicola Fusco, Massimo Barberis, Giancarlo Cancers.2020; 12(7): 1800. CrossRef
PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy Ana Bocanegra, Ester Blanco, Gonzalo Fernandez-Hinojal, Hugo Arasanz, Luisa Chocarro, Miren Zuazo, Pilar Morente, Ruth Vera, David Escors, Grazyna Kochan International Journal of Molecular Sciences.2020; 21(16): 5918. CrossRef
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer Danny Rischin, Marta Gil-Martin, Antonio González-Martin, Irene Braña, June Y. Hou, Daniel Cho, Gerald S. Falchook, Silvia Formenti, Salma Jabbour, Kathleen Moore, Aung Naing, Kyriakos P. Papadopoulos, Joaquina Baranda, Wen Fury, Minjie Feng, Elizabeth St Gynecologic Oncology.2020; 159(2): 322. CrossRef
Atezolizumab: A Review in Extensive-Stage SCLC James E. Frampton Drugs.2020; 80(15): 1587. CrossRef
Prognostic and clinicopathological roles of programmed death‐ligand 1 (PD‐L1) expression in thymic epithelial tumors: A meta‐analysis Hyun Min Koh, Bo Gun Jang, Hyun Ju Lee, Chang Lim Hyun Thoracic Cancer.2020; 11(11): 3086. CrossRef
Präzisionsmedizin bei NSCLC im Zeitalter der Immuntherapie: Neue Biomarker zur Selektion der am besten geeigneten Therapie oder des am besten geeigneten Patienten Giovanni Rossi, Alessandro Russo, Marco Tagliamento, Alessandro Tuzi, Olga Nigro, Giacomo Vollome, Claudio Sini, Massimiliano Grassi, Maria Giovanna Dal Bello, Simona Coco, Luca Longo, Lodovica Zullo, Enrica Teresa Tanda, Chiara Dellepiane, Paolo Pronzato Kompass Pneumologie.2020; 8(6): 300. CrossRef
Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation Lee, Kim, Sung, Lee, Han, Kim, Choi International Journal of Molecular Sciences.2019; 20(19): 4794. CrossRef
Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers João Lobo, Ângelo Rodrigues, Rita Guimarães, Mariana Cantante, Paula Lopes, Joaquina Maurício, Jorge Oliveira, Carmen Jerónimo, Rui Henrique Cancers.2019; 11(10): 1535. CrossRef
Basis of PD1/PD-L1 Therapies Barbara Seliger Journal of Clinical Medicine.2019; 8(12): 2168. CrossRef
BACKGROUND The aim of this study was to determine whether pyrosequencing (PSQ) might be useful to achieve O6-methyl guanine methyltransferase (MGMT) promoter methylation using 1- to 13-year-old archival tissues as a clinical biomarker in routine practice. METHODS The study included 141 formalin-fixed paraffin-embedded (FFPE) glial tumors from the archives of the Pathology Department from 1997-2010. RESULTS The average percentage of methylation (MP) of the 141 cases was 14.0+/-16.8%, and methylated cases were 32.3+/-14.9%. The average MP of each year did not show a linear increasing or decreasing pattern according to the age of the FFPE block (p=0.771). The average MP of methylated glioblastomas was 35.8+/-14.7%, 31.8+/-15.5% for anaplastic astrocytomas, and 22.4+/-15.1% for astrocytoma. A tendency was observed toward an increasing pattern of average MP with World Health Organization (WHO) grade (p=0.063) in astrocytic tumors. A correlation was observed between average MP and WHO grade (p=0.038) and a bimodal distribution was observed between the methylated and unmethylated cases, using a 9% cut-off value (p<0.001). CONCLUSIONS The results showed that a quantitative approach for MGMT promoter methylation yielded a 100% success rate for FFPE tissues from archives. PSQ can be used in a retrospective trial, but the cut-off value and calculation method should be further validated.
Citations
Citations to this article as recorded by
Immunohistochemical Classification of Primary and Secondary Glioblastomas Kyu Sang Lee, Gheeyoung Choe, Kyung Han Nam, An Na Seo, Sumi Yun, Kyung Ju Kim, Hwa Jin Cho, Sung Hye Park Korean Journal of Pathology.2013; 47(6): 541. CrossRef